Late toxicity and biochemical control in 554 prostate cancer patients treated with and without dose escalated image guided radiotherapy

Radiotherapy and Oncology

Volumn 107, Issue 2, 2013, Pages 140-146

  Kok, David ^a,b   Gill, Suki ^a   Bressel, Mathias ^a   Byrne, Keelan ^a   Kron, Tomas ^a   Fox, Chris ^a   Duchesne, Gillian ^a,c   Tai, Keen Hun ^a,c   Foroudi, Farshad ^a,c  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Dose escalation; Fiducial markers; IGRT; Late toxicity; Prostate cancer

Indexed keywords

ANDROGEN DEPRIVATION THERAPY; ARTICLE; BIOCHEMICAL FAILURE FREE SURVIVAL; CANCER PATIENT; CANCER RECURRENCE; DIABETES MELLITUS; EXTERNAL BEAM RADIOTHERAPY; FIDUCIAL MARKER; GASTROINTESTINAL TOXICITY; GLEASON SCORE; HEART INFARCTION; HUMAN; HYPERTENSION; IMAGE GUIDED RADIOTHERAPY; INTENSITY MODULATED RADIATION THERAPY; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE ESCALATION; RETROSPECTIVE STUDY; STAGING; TRANSURETHRAL RESECTION; UROGENITAL TRACT DISEASE;

HUMANS; MALE; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; RADIOTHERAPY, IMAGE-GUIDED; RETROSPECTIVE STUDIES;

EID: 84879020779     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2013.04.007     Document Type: Article

References (24)

1. B.A. Jereczek-Fossa, and R. Orecchia Evidence-based radiation oncology: definitive, adjuvant and salvage radiotherapy for non-metastatic prostate cancer Radiother Oncol 84 2007 197 215 (Pubitemid 47299139)
2. C. Mettlin Changes in patterns of prostate cancer care in the United States: results of American college of surgeons commission on cancer studies. 1974-1993 Prostate 32 1997 221 226 (Pubitemid 27337957)
3. M.R. Cooperberg, J.M. Broering, and P.R. Carroll Time trends and local variation in primary treatment of localized prostate cancer J Clin Oncol 28 2010 1117 1123
4. A. Pollack, G. Zagars, and G. Starkschall Prostate cancer radiation dose response: results of the M.D. Anderson phase III randomized trial Int J Radiat Oncol Biol Phys 53 2002 1097 1105 (Pubitemid 34787842)
5. D.A. Kuban, S.L. Tucker, and L. Dong Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer Int J Radiat Oncol Biol Phys 70 2008 67 74 (Pubitemid 350251041)
6. D. Dearnaley, M. Sydes, and J. Graham Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial Lancet Oncol 8 2007 475 487 (Pubitemid 46805903)
7. D.P. Dearnaley, V.S. Khoo, and A. Norman Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial Lancet 353 1999 267 272 (Pubitemid 29088118)
8. S.T. Peeters, W.D. Heemsbergen, and P.C. Koper Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy J Clin Oncol 24 2006 1990 1996 (Pubitemid 46622106)
9. A. Zietman, M. DeSilvio, and J. Slater Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial JAMA 294 2005 1233
10. U. van der Heide, A. Kotte, and H. Dehnad Analysis of fiducial marker-based position verification in the external beam radiotherapy of patients with prostate cancer Radiother Oncol 82 2007 38 45 (Pubitemid 46097130)
11. A. Thompson, C. Fox, and F. Foroudi Planning and implementing an implanted fiducial programme for prostate cancer radiation therapy J Med Imaging Radiat Oncol 52 2008 419 424
12. L.A. Dawson, and M.B. Sharpe Image-guided radiotherapy: rationale, benefits, and limitations Lancet Oncol 7 2006 848 858 (Pubitemid 44464078)
13. A.J. Nederveen, H. Dehnad, and U.A. van der Heide Comparison of megavoltage position verification for prostate irradiation based on bony anatomy and implanted fiducials Radiother Oncol 68 2003 81 88 (Pubitemid 37289340)
14. I. Gauthier, J.F. Carrier, and D. Beliveau-Nadeau Dosimetric impact and theoretical clinical benefits of fiducial markers for dose escalated prostate cancer radiation treatment Int J Radiat Oncol Biol Phys 74 2009 1128 1133
15. M. Ghilezan, D. Yan, and J. Liang Online image-guided intensity-modulated radiotherapy for prostate cancer: how much improvement can we expect? A theoretical assessment of clinical benefits and potential dose escalation by improving precision and accuracy of radiation delivery Int J Radiat Oncol Biol Phys 60 2004 1602 1610 (Pubitemid 39601878)
16. D. Skarsgard, P. Cadman, and A. El-Gayed Planning target volume margins for prostate radiotherapy using daily electronic portal imaging and implanted fiducial markers Radiother Oncol 5 2010 52 63
17. CTCAE V4.0, Cancer therapy evaluation program, National Cancer Institute; 2010. Available from: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14- QuickReference-5x7.pdf.
18. S. Gill, J. Thomas, and C. Fox Acute toxicity in prostate cancer patients treated with and without image-guided radiotherapy Radiat Oncol 6 2011 145
19. M. Roach 3rd, G. Hanks, and H. Thames Jr. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix consensus conference Int J Radiat Oncol Biol Phys 65 2006 965 974
20. A. Harsolia, C. Vargas, and D. Yan Predictors for chronic urinary toxicity after the treatment of prostate cancer with adaptive three-dimensional conformal radiotherapy: dose-volume analysis of a phase II dose-escalation study Int J Radiat Oncol Biol Phys 69 2007 1100 1109 (Pubitemid 47625853)
21. M. Cheung, S. Tucker, and L. Dong Investigation of bladder dose and volume factors influencing late urinary toxicity after external beam radiotherapy for prostate cancer Int J Radiat Oncol Biol Phys 67 2007 1059 1065
22. M. Zelefsky, M. Kollmeier, and B. Cox Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer Int J Radiat Oncol Biol Phys 84 2012 125 129
23. CTCAE v2.0. Bethesda (MD): National Cancer Institute; 1999.
24. A. Trotti, D. Colevas, and A. Setser CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment Sem Radiat Oncol 13 2003 176 181 (Pubitemid 36962641)